Clinical Trials Logo

Filter by:
NCT ID: NCT06090305 Recruiting - Multiple Sclerosis Clinical Trials

Effectiveness of a Digital Health Application for Multiple Sclerosis (Levidex)

LAMONT
Start date: November 20, 2023
Phase: N/A
Study type: Interventional

The trial aims to evaluate the effectiveness of a novel digital health application (levidex), which was designed to increase quality of life in persons with multiple sclerosis (MS). Therefore, 470 people with MS will be recruited and randomized to two groups: (1) an intervention group that will receive access to levidex in addition to treatment as usual (TAU) (n = 235) and (2) a control group receiving an overview of relevant brochures from the Deutsche Multiple Sklerose Gesellschaft (German Multiple Sclerosis Society) on the topic of lifestyle in MS in addition to TAU (n = 235).The primary outcome measure is the total score on the Hamburg Quality of Life Questionnaire for Multiple Sclerosis (HALEMS), collected 6 months post-randomization.

NCT ID: NCT06088966 Recruiting - Cardiac Output, Low Clinical Trials

Evaluation of Hemodynamic and Ventilatory Effects of Negative Pressure Ventilation

Start date: August 1, 2023
Phase:
Study type: Observational

Investigation of the effects of negative pressure ventilation after cardiac surgery in adults onto performance of the left and right heart and the lungs.

NCT ID: NCT06088615 Recruiting - Healthy Clinical Trials

Feasibility of Non-invasive Glucose Monitoring by Using Photothermal Deflectometry

Start date: November 8, 2023
Phase:
Study type: Observational

This study aims to evaluate the feasibility of non-invasive glucose monitoring by using photothermal deflectometry in the interstitial fluid of the skin on the wrist of subjects with diabetes mellitus type 1 and 2.

NCT ID: NCT06088290 Recruiting - Leiomyosarcoma Clinical Trials

Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma

SaLuDo
Start date: September 21, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The primary objective of this phase IIb/III study is to evaluate whether the combination of lurbinectedin plus doxorubicin given as first line treatment for metastatic leiomyosarcoma (LMS) prolongs the progression-free survival (PFS) by Independent Review Committee (IRC) when compared to doxorubicin administered as a single agent.

NCT ID: NCT06087835 Recruiting - Clinical trials for Chronic Kidney Disease With High Proteinuria

Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)

Start date: November 7, 2023
Phase: Phase 3
Study type: Interventional

This is a Phase III, randomised, multicentre, double-blinded study to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney disease (CKD) and high proteinuria.

NCT ID: NCT06087627 Recruiting - Prurigo Nodularis Clinical Trials

A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine

CLEAR PN
Start date: December 27, 2023
Phase:
Study type: Observational [Patient Registry]

Prurigo nodularis (PN) is a skin disease characterized by the presence of single to multiple symmetrically distributed, intensively itching nodules. The main symptom is uncontrollable itching leading to prolonged, repetitive, and uncontrollable rubbing, scratching which in turn causes injuries to the skin. In recent years, number of studies evaluating PN, the affected population and the disease burden has increased but PN remains still understudied. This non-interventional study is intended to describe the long-term effectiveness of dupilumab (Dupixent®) in participants aged 18 years or older and suffering from moderate-to-severe PN who receive dupilumab for PN treatment in a real-world setting in Germany according to the prescribing information (Summary of Product Characteristics [SmPC]). The decision to initiate dupilumab treatment is made by the treating physician and participant according to the participant's medical need and to the standard of best medical practice. This decision is made independently and before data inclusion in this non-interventional study.

NCT ID: NCT06086184 Recruiting - Psychotic Disorders Clinical Trials

Inpatient Group Acceptance and Commitment Therapy (ACT) for Psychosis Spectrum Disorder

ASPIRE
Start date: October 16, 2023
Phase: N/A
Study type: Interventional

The pilot study that will serve as the basis for the larger project - a multicenter randomized controlled single-blinded trial (RCT) will focus on testing the feasibility and efficacy of an inpatient group ACT treatment program and its effects on symptom severity and patient satisfaction in patients with psychosis spectrum disorder. The ACT-specific treatment program for inpatients with psychosis spectrum disorder is designed to enable patients to deal with their disease in an accepting manner over the long term, to promote self-determined and positive attitudes toward treatment and support options, and thus to reduce rehospitalization rates.

NCT ID: NCT06084169 Recruiting - Cataract Clinical Trials

Investigation for Assessing the Visual Performance of Hanita Lenses Intensity SL IOL in Comparison to Alcon Panoptix IOL

Start date: July 13, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare the visual performance between Intensity SL IOL and Panoptix IOL in men and women diagnosed with cataract who require cataract surgery procedure that meet the inclusion criteria and provide written informed consent will be enrolled in the study. The main questions it aims to answer are: 1. To show non-inferiority in binocular distance corrected visual acuity for far, intermediate and near distances after Trifocal IOL implantation. 2. To show non-inferiority in the Defocus Curve measurement 3. To show non-inferiority in Contrast Sensitivity measurement 4. To show non-inferiority in patient satisfaction Participants will attend a total of 10 study visits: 1 preoperative visit, 2 operations and 7 postoperative visits.

NCT ID: NCT06083311 Recruiting - Clinical trials for Functional Constipation

The Efficacy of a Probiotic for Functional Constipation (FC)

SLOG
Start date: October 19, 2023
Phase: N/A
Study type: Interventional

Investigate the effect of a probiotic (live bacteria) in individuals with functional constipation.

NCT ID: NCT06079879 Recruiting - Clinical trials for Essential Thrombocythemia

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

Start date: December 31, 2023
Phase: Phase 3
Study type: Interventional

This is a study evaluating the safety and efficacy of bomedemstat (MK-3543) compared with the best available therapy (BAT) in participants with essential thrombocythemia (ET) who have an inadequate response to or are intolerant of hydroxyurea. The primary study hypothesis is that bomedemstat is superior to the best available therapy with respect to durable clinicohematologic response (DCHR).